{"id":14122,"date":"2026-03-30T09:04:58","date_gmt":"2026-03-30T07:04:58","guid":{"rendered":"https:\/\/leo-foundation.org\/en\/?p=14122"},"modified":"2026-03-30T09:05:24","modified_gmt":"2026-03-30T07:05:24","slug":"dkk-59-million-to-further-advance-research-in-inflammatory-skin-diseases","status":"publish","type":"post","link":"https:\/\/leo-foundation.org\/en\/2026\/03\/30\/dkk-59-million-to-further-advance-research-in-inflammatory-skin-diseases\/","title":{"rendered":"DKK 59 million to further advance research in inflammatory skin diseases"},"content":{"rendered":"\n
Executive Director (alternating), Professor and PI of Bioskin Jeanne Duus Johansen \u2013 Research Leader Marianne Bengtson L\u00f8vendorf \u2013 Executive Director (alternating), Professor and PI of of Bioskin Lone Skov \u2013 Research Leader Malin Glindvad Ahlstr\u00f6m \u2013 Chief Physician Claus Zachariae. All affiliated with the Department of Allergy and Dermatology at Herlev and Gentofte Hospital.<\/em><\/p>\n\n\n\n 30 March 2026<\/em><\/p>\n\n\n\n Chronic inflammatory skin diseases such as psoriasis, atopic dermatitis, and contact dermatitis affect around 10% of the global population. These conditions often have a profound impact on patients\u2019 quality of life, yet many aspects of their underlying disease mechanisms remain poorly understood.<\/p>\n\n\n\n To support the continued work on this challenge, the LEO Foundation has awarded DKK 59 million for BIOSKIN 2.0 \u2013 the next phase of the research program and biobank, hosted by the Department of Dermatology and Allergy at Herlev and Gentofte Hospital.<\/p>\n\n\n\n Expanding a unique clinical research platform<\/strong><\/p>\n\n\n\n Since its launch in 2021, BIOSKIN has established a large-scale clinical research platform and biobank combining clinical data, biological samples, and advanced molecular analyses to better understand chronic inflammatory skin diseases. The program already includes more than 5,000 clinical visits from 1,500 participating patients, who contribute to the creation of a unique resource for dermatology research. The goal is to collect clinical data as well as skin and blood samples from 3,000 patients.<\/p>\n\n\n\n BIOSKIN 2.0 will build on this foundation by continuing the recruitment of patients while expanding the program to include additional skin conditions such as hidradenitis suppurativa, alopecia areata and vitiligo. This phase of the program will also focus on large-scale data analysis, integrating clinical data with high-dimensional molecular datasets to identify biomarkers that can help predict disease progression and treatment response for skin disease patients in the future.<\/p>\n\n\n\n \u201cThe LEO Foundation supports research with the potential to translate new knowledge into better prevention, diagnosis and treatment of skin diseases. BIOSKIN 2.0 is a strong example of a long-term grant where we support the development of research resources as well as research infrastructure. This combination can help accelerate scientific progress and bring us closer to more targeted and personalized treatments. At the same time, the work strengthens the important interaction between clinical practice, research and patients and helps advance the field both nationally and internationally,\u201d says Anne-Marie Engel, Chief Scientific Officer at the LEO Foundation.<\/p>\n\n\n\nA major grant from the LEO Foundation will support the next phase of the BIOSKIN research program and biobank at\u00a0Copenhagen University Hospital \u2013 Herlev and Gentofte. BIOSKIN\u2019s research brings together patient data, biospecimens and advanced molecular analyses to advance more targeted and personalized treatments for skin diseases.<\/h3>\n\n\n\n